Home
Scorpion Therapeutics, Inc.

Scorpion Therapeutics, Inc. Market Share Analysis for November 2025

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

Health > Biotechnology and Pharmaceuticals

Domainscorpiontx.com

Year Founded2020

Employees51 - 200

Annual Revenue< $1M

Scorpion Therapeutics, Inc.

Scorpion Therapeutics, Inc. (including company regionals)

scorpiontx.com

See more website traffic and engagement information

Total visits to Scorpion Therapeutics, Inc.'s top domains

Understand Scorpion Therapeutics, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Scorpion Therapeutics, Inc.'s top domains

Analyze Scorpion Therapeutics, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Scorpion Therapeutics, Inc.'s top domains

See how Scorpion Therapeutics, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Scorpion Therapeutics, Inc. top competitors by domain

Top similar sites in November 2025, ranked by their affinity

entradatx.comCompany NameEntrada TherapeuticsEmployees51 - 200HQUnited States, Massachusetts, BostonAnnual revenue$200M - $500MTotal visits8.3KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Scorpion Therapeutics, Inc.

These are the website technologies, by industry, used by Scorpion Therapeutics, Inc. top domains

Widget (4)

Twemoji

Mobile (2)

Meta Viewport

Social (2)

Instagram

Advertising (1)

PubMatic

More Technologies

9

See all

News & Signals from Scorpion Therapeutics, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsScorpion Therapeutics, Inc. partnered with Pierre Fabre Group on Apr 1st '23.Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs.

NewsScorpion Therapeutics, Inc. attends event ESMO Congress 2024.Scorpion Therapeutics presents Initial Clinical Data from its Phase 1/2 trial of STX-478 demonstrating potentially best-in-class mutant-selective PI3Kα inhibition for the treatment of Advanced Solid Tumors at ESMO Congress 2024.

NewsScorpion Therapeutics, Inc. receives financing of $150M in Series C.Scorpion Therapeutics raises USD 150M Series C financing.